> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Oncology Panel to Discuss Polivy sBLA for Lymphoma
- URL: https://www.fdaweb.com/oncology-panel-to-discuss-polivy-sbla-for-lymphoma/
- Published: 2023-01-26T12:00:00.000Z
- Updated: 2026-09-14T18:13:26.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5153629

*Federal Register* notice: FDA has announced a 3/9 Oncologic Drugs Advisory Committee meeting to discuss a supplemental BLA for Polivy (polatuzumab vedotin-piiq) for injection. The submission proposes an indication for combination use with a rituximab product, cyclophosphamide, doxorubicin, and prednisone for treating adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL). Polivy was granted accelerated approval in 2019 for use in combination with bendamustine and a rituximab product for treating adult patients with relapsed or refractory DLBCL, not otherwise specified, after at least two prior therapies. The new submission is based on data from a confirmatory study, POLARIX (Study GO39942), that was required as part of the 2019 accelerated approval. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2023-01-26/pdf/2023-01553.pdf?ref=fdaweb.com).